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Background. Psychological stress is commonly thought to increase the risk of herpes zoster by causing immunosuppression. 
However, epidemiological studies on the topic are sparse and inconsistent. We conducted 2 parallel case-control studies of the asso-
ciation between partner bereavement and risk of zoster using electronic healthcare data covering the entire Danish population and 
general practices in the UK Clinical Practice Research Datalink.
Methods. We included patients with a zoster diagnosis from the primary care or hospital-based setting in 1997–2013 in Denmark 
(n = 190 671) and 2000–2013 in the United Kingdom (n = 150 207). We matched up to 4 controls to each case patient by age, sex, and 
general practice (United Kingdom only) using risk-set sampling. The date of diagnosis was the index date for case patients and their 
controls. We computed adjusted odds ratios with 99% confidence intervals for previous bereavement among case patients versus 
controls using conditional logistic regression with results from the 2 settings pooled using random-effects meta-analysis.
Results. Overall, the adjusted odds ratios for the association between partner bereavement and zoster were 1.05 (99% confidence 
interval, 1.03–1.07) in Denmark and 1.01 (.98–1.05) in the United Kingdom. The pooled estimates were 0.72, 0.90, 1.10, 1.08, 1.02, 
1.04, and 1.03 for bereavement within 0–7, 8–14, 15–30, 31–90, 91–365, 366–1095, and >1095 days before the index date, respectively.
Conclusions. We found no consistent evidence of an increased risk of zoster after partner death. Initial fluctuations in estimates 
may be explained by delayed healthcare contact due to the loss.
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It is commonly thought that severe psychological stress can pro-
voke reactivation of latent herpesviruses, including the varicella 
zoster virus, which causes herpes zoster (HZ) [1]. This belief 
is supported by immunological studies demonstrating activa-
tion of the hypothalamic-pituitary-adrenal axis and inhibition 
of natural killer cell activity, phagocytosis, and cytotoxic T-cell 
activity in response to stress [1–3]. However, epidemiological 
data assessing stress as a risk factor for HZ are sparse and incon-
sistent [4–8].
Five studies have examined the association between negative 
life events and HZ, with some reporting at least a 40% increase 
in relative risk up to 4 years after the event [4–7], whereas oth-
ers report no association [8]. This lack of consistent evidence 
may be explained by the difficulty of measuring psychological 
stress, given variation among persons in the types of life events 
perceived as stressful. Indeed, various measures of stress were 
employed (eg, health events in partners [8] or the Geriatric 
Scale of Recent Life Events [5, 6]) in the previous studies.
The death of a loved one is considered extremely stressful 
[9]. It is likely to affect most persons gravely regardless of 
coping mechanisms [10], making it a useful model for stud-
ying the effects of psychological stress. We therefore exam-
ined whether partner bereavement was associated with HZ 
in 2 parallel case-control studies in Denmark and the United 
Kingdom.
METHODS
Data Sources
Denmark and the United Kingdom have publicly funded 
healthcare systems [11, 12]. Primary healthcare is delivered 
by general practitioners, who act as gatekeepers to specialized 
secondary care provided at hospitals. Prescription drugs are 
partially or fully reimbursed, although reimbursement schemes 
differ slightly between the countries.
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In Denmark, we used nationwide registries to obtain data on 
all inpatient and outpatient contacts with nonpsychiatric hospi-
tals (the Danish National Patient Registry [13]) and psychiat-
ric hospitals (the Danish Psychiatric Central Research Registry 
[14]); prescriptions dispensed at community pharmacies (the 
Danish National Prescription Registry [15]; patients receiving 
care for diabetes (the Danish National Diabetes Registry [16]); 
education (the Population Education Registry [17]); and gen-
eral demographic data, for example, civil status and vital status 
(the Civil Registration System [18]).
The main data source for the UK study was the Clinical 
Practice Research Datalink (CPRD), which contains electronic 
primary healthcare records for approximately 7% of the UK 
population [19]. Sixty percent of participating practices allow 
linkage with hospital inpatient data (the Hospital Episode 
Statistics database [20]) and individual-level social data (the 
Index of Multiple Deprivation [21]), which were also used in 
the present study. Further details about the data sources are pro-
vided in Supplementary Appendix 1.
The Danish study was approved by the Danish Data 
Protection Agency (record number: 2013-41-1719). Danish leg-
islation does not require approval by an ethical review board or 
informed consent from patients for registry-based studies. The 
British study was approved by the CPRD Independent Scientific 
Advisory Committee (record number: 15_248) and the London 
School of Hygiene and Tropical Medicine Ethics Committee 
(record number: 11219). Study protocols, including complete 
code lists, are available as supplementary data.
Study Population
We included persons with a first-time diagnosis of HZ 
recorded in general practice or with a primary (first-listed) 
hospital-based diagnosis of HZ between 1997 and 2013 
in Denmark and between 2000 and 2013 in the United 
Kingdom. Hospital-based diagnoses were available in both 
settings. However, while general practitioners in the CPRD 
register reasons for patient contact using Read Codes, diag-
noses of HZ are not recorded in primary care in Denmark. 
As a surrogate measure for HZ treated in this setting, we 
therefore used the Danish National Prescription Registry to 
identify prescriptions for systemic acyclovir, valacyclovir, and 
famciclovir at tablet doses most likely to represent treatment 
for HZ (800 mg acyclovir in packages with 35 pills or a 500-
mg tablet dose of valacyclovir or famciclovir) [22]. Persons 
with any previous prescription for 1 of the 3 antivirals were 
ineligible, because repeated use is more common for com-
peting indications (ie, reactivating herpes simplex). Given 
that herpes simplex is most frequent in young persons [23], 
we included only individuals aged ≥40 years in Denmark as 
well as in the United Kingdom (for comparability). To avoid 
including patients with long-term HZ-related complications, 
persons were ineligible if they had any previous diagnosis of 
postherpetic neuralgia from general practice (not available in 
Denmark) or the hospital-based setting or if they had a hospi-
tal-based HZ diagnosis not recorded as the primary diagnosis 
for the hospital contact. In the UK study, we also required that 
persons had been registered with their current general prac-
tice for ≥12 months before the index date to exclude past his-
tory of HZ recorded shortly after registration [24]. The index 
date for case patients was the earliest of the following: date 
of primary care diagnosis (date a relevant antiviral drug was 
dispensed in Denmark), date of hospital admission, or start of 
outpatient clinic follow-up.
We individually matched up to 4 population controls to 
each case patient by age, sex, and general practice (the United 
Kingdom only) using risk-set sampling [25] from the Civil 
Registration System in Denmark and from the CPRD in the 
United Kingdom. We gave preference to controls who were 
closest in age to the case patient, allowing a 2-month differ-
ence in Denmark and up to 1  year in the United Kingdom, 
where only year of birth was available. Controls were assigned 
the same index date as their case patient, and we applied the 
same inclusion criteria. In the United Kingdom, we excluded 
inactive controls (persons with no consultation record in 
the CPRD in the period 6 months before to 12 months after 
the index date) after matching [26]. In the main analysis, 
case patients and controls were included regardless of part-
ner/civil status. Because the HZ vaccine was introduced in 
September 2014 in Denmark and in September 2013 in the 
United Kingdom, the vast majority of study participants were 
unvaccinated.
Partner Bereavement
The full exposure definitions are summarized in Supplementary 
Appendix 2. In the Danish study, we identified partners using 
an algorithm developed by Statistics Denmark, a govern-
ment-funded institution responsible for collecting, processing, 
and publishing data for various scientific purposes [27]. The 
algorithm combines data on civil status, kinship, exact address, 
birth year, and sex registered in the Civil Registration System 
to identify partners (married persons, same-sex couples living 
in a registered partnership, and nonmarried cohabitating cou-
ples). Because the personal identifiers for the couple are availa-
ble, it was possible to accurately identify the vital status of case 
patients’ and controls’ current or previous partners.
In the United Kingdom, we adapted a previously described 
method to identify partners in the CPRD based on the “fam-
ily number,” which identifies persons in a practice who live in 
the same household or who are otherwise associated (eg, live in 
the same institution) [28]. Cohabitees were classified as part-
ners if they were persons of the opposite sex, with an age gap of 
≤10 years, and with no younger adult in the household within 
≤15 years of age of either person in the couple [28]. We applied 
these age criteria to avoid misclassifying the death of a child 
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as partner bereavement. We did not consider cohabitees to be 
partners if the case patient or control had codes in the primary 
care record indicating residence in a communal establishment 
before the index date, if both individuals in the couple were 
aged ≥95 years, and/or if the same family number was used for 
>10 persons registered with the practice. We used the death 
date in the deceased partner’s primary care record as the date 
of bereavement.
To explore whether the association between bereavement and 
HZ depended on whether the death of a partner was unfore-
seen, we computed their age-adjusted Charlson Comorbidity 
Index score, in both UK and Danish data. This index assigns 
0–6 points to various chronic diseases according to their ability 
to predict death, with additional points given according to age 
[29]. Based on the total score, we categorized risk of partner 
death as low (0–3 points), intermediate (4–6 points), or high 
(≥7 points). We excluded records within the month before 
death to avoid including diagnoses coded retrospectively at 
death (eg, the cause of death). As an alternative measure in the 
UK study, we also examined primary care and hospital records 
for terminal disease among partners before time of death 
(Supplementary Appendix 2).
Statistical Analysis
We used conditional logistic regression to compute unad-
justed odds ratios (ORs) associating previous partner bereave-
ment with HZ. We selected 99% confidence intervals (CIs) as 
a measure of precision and based interpretations on clinical 
significance of the point estimates rather than dichotomiz-
ing to statistical significance according to an arbitrary signif-
icance level [30]. Given the risk-set sampling of controls, the 
ORs provide an unbiased estimate of the incidence rate ratios 
[25]. In multivariable analyses, we also adjusted for potential 
risk factors for HZ [26], including previous records of rheuma-
toid arthritis, systemic/subacute lupus erythematosus, inflam-
matory bowel disease, chronic obstructive pulmonary disease, 
asthma, diabetes, chronic kidney disease, human immunodefi-
ciency virus infection, hematopoietic stem cell or bone marrow 
transplantation, solid organ transplantation, or other cellular 
immune deficiency at any time before index date; leukemia, 
lymphoma or myeloma within 2  years before the index date; 
and prescription records for oral glucocorticoids, other immu-
nosuppressant drugs, or inhaled glucocorticoids within 90 days 
before the index date (see Supplementary Appendix 2 for defi-
nitions used). 
We hypothesized that an increase in risk of HZ would be 
most pronounced within the first 3 months after bereavement. 
Within this 3-month period there could further be some varia-
tion related to the time from bereavement to decline in immu-
nity and onset of HZ. To detect discrete fluctuations in the 
OR, we therefore examined the association between HZ and 
partner bereavement within 0–7, 8–14, 15–30, 31–90, 91–365, 
366–1095, or >1095  days before the index date. Persons who 
had not previously experienced partner death provided the ref-
erence in all comparisons. As the Danish and UK studies were 
designed to resemble each other closely, we pooled the main 
results using DerSimonian and Lairds’ random-effects model 
[31]. We used the I2 statistic to estimate the percentage of incon-
sistency between study estimates that cannot be explained by 
chance alone [32].
In stratified analyses, we examined whether ORs for bereave-
ment within 0–30 days before the index date depended on risk 
of partner death (based on their Charlson Comorbidity Index 
and records of terminal disease), age, or sex. We also deter-
mined whether ORs were higher among persons with medical 
records indicating depression or anxiety within 90 days before 
the index date, because we hypothesized that bereavement may 
provoke or exacerbate these conditions [10] and thereby cause 
HZ [26].
Sensitivity Analyses
We performed several planned sensitivity analyses, described 
in more detail in Supplementary Appendix 3.  Briefly, we 
first repeated the stratified analyses using a 90-day exposure 
window. Second, we excluded single subjects from the refer-
ence group. Third, we adjusted for individual-level measures 
of socioeconomic status, as it may be associated both with 
inequality in life expectancy (and thus probability of partner 
death) and with timely healthcare seeking for HZ. We used 
highest level of achieved education in Denmark (available 
for 90%) and quintiles of the patient-level Index of Multiple 
Deprivation scores in the United Kingdom (available for 
60%). Fourth, in the UK study, we examined the impact of 
adjusting for smoking status, alcohol consumption, and body 
mass index. Because data were missing for 12% of subjects 
in this analysis, we used both a complete-case approach and 
multiple imputation by chained equations [33]. Valid lifestyle 
data were not available in the Danish study [34]. Finally, we 
repeated the Danish analyses after excluding case patients 
identified based on prescriptions for which the indication 
code did not state HZ. We did not use indication codes for 
the main analyses due to incomplete and unspecific coding. 
We performed all analyses using the Stata statistical software 
package (StataCorp).
RESULTS
We included 190 671 HZ case patients and 762 684 controls in 
the Danish study and 150 207 HZ case patients and 576 878 con-
trols in the UK study (Figure 1). Median age was approximately 
65 years, and >60% were women (Table 1). The relative distri-
bution of HZ risk factors among case patients versus controls 
was very similar in the 2 studies, although absolute numbers 
differed, particularly for asthma, chronic kidney disease, and 
inhaled glucocorticoids (Supplementary Appendix 3).
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The adjusted OR for any previous partner bereavement was 
1.05 (99% CI, 1.03–1.07) in Denmark and 1.01 (.98–1.05) in the 
United Kingdom (Table 2). Unadjusted and adjusted ORs were 
very similar. The I2 statistics from the meta-analysis were <20% 
within 0–90  days before the index date (Figure  2). Although 
we found evidence of statistical heterogeneity for remain-
ing exposure windows, the effect estimates were similar, and 
neither study supported a substantial increase in relative risk. 
We therefore combined the estimates for all periods. The pooled 
adjusted ORs were 0.72 (99% CI, .47–1.12), 0.90 (.55–1.46), 1.10 
(.83–1.45), 1.08 (.95–1.23), 1.02 (.91–1.14), 1.04 (1.00–1.10), 
and 1.03 (.98–1.06) within 0–7, 8–14, 15–30, 31–90, 91–365, 
366–1095, and >1095 days before the index date, respectively. 
In both settings, the suggestion of an initial decrease in the OR 
Denmark
190 671 case patients with
incident herpes zoster
150 663 case patients with
incident herpes zoster
408 case patients 
without
eligible controls
48 case patients 
with no active
controls left
150 207 case patients; 
576 878 controls
190 671 case patients; 
762 684 controls
United Kingdom
Figure 1. Flowchart for the studies. Inclusion criteria for case patients and controls were age ≥40 years; no previous Read Code or International Classification of Diseases, 
10th revision, code for postherpetic neuralgia; no previous prescription for systemic acyclovir, valacyclovir, or famciclovir (Denmark only); and registration with current general 
practice for ≥12 months before the index date (United Kingdom only).
Table 1. Distribution of Matching Factors Among Herpes Zoster Case Patients and Controls
Factor
Denmark, No. (%)a United Kingdom, No. (%)a
Case Patients 
(n = 190 671)
Controls  
(n = 762 684)
Case Patients 
(n = 150 207)
Controls
(n = 576 878)
Sex
 Female 125 526 (65.8) 502 104 (65.8) 90 501 (60.3) 354 057 (61.4)
 Male 65 145 (34.2) 260 580 (34.2) 59 706 (39.7) 222 821 (38.6)
Age at index date, median (IQR), y 64 (53–75) 64 (53–75) 65 (55–75) 65 (55–75)
Age group at index date
 40–49 y 34 838 (18.3) 139 352 (18.3) 20 844 (13.9) 77 009 (13.3)
 50–59 y 41 898 (22.0) 167 592 (22.0) 33 632 (22.4) 127 508 (22.1)
 60–69 y 45 662 (23.9) 182 648 (23.9) 38 437 (25.6) 150 110 (26.0)
 70–79 y 39 264 (20.6) 157 056 (20.6) 34 767 (23.1) 136 694 (23.7)
 80–89 y 23 968 (12.6) 95 872 (12.6) 19 454 (13.0) 75 566 (13.1)
 ≥90 y 5041 (2.6) 20 164 (2.6) 3073 (2.0) 9991 (1.7)
Socioeconomic status (practice level)
 1 (least deprived) … … 29 889 (19.9) 114 855 (19.9)
 2 … … 29 529 (19.7) 113 395 (19.7)
 3 … … 32 306 (21.5) 124 101 (21.5)
 4 … … 30 580 (20.4) 117 216 (20.3)
 5 (most deprived) … … 27 903 (18.6) 107 311 (18.6)
Abbreviation: IQR, interquartile range. 
aData represent No. (%) of case patients or controls, unless otherwise specified.
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observed within 14 days before the index date was followed by a 
compensatory increase within 15–90 days.
We found no substantial variation in estimates after strati-
fying by risk of partner death, age, sex, or recent depression/
anxiety (Figure  3 and Supplementary Appendix 3). However, 
meaningful comparisons were hampered by very wide CIs. 
Results were robust in all sensitivity analyses (Supplementary 
Appendix 3).
DISCUSSION
This large population-based study using data from Denmark 
and the United Kingdom found no evidence of a substantially 
increased relative risk of HZ after partner bereavement. Data 
from the 2 settings showed similar distribution of well-known 
risk factors for HZ and effect estimates of similar magnitude for 
risk of HZ after bereavement.
Our findings corroborate a recent self-controlled case 
series [8]. Among 39 811 persons experiencing death or an 
intensive care unit stay lasting >14  days for a previously 
healthy spouse (insurance cobeneficiaries within 5 years of 
age and of opposite sex), 59 persons were diagnosed with 
HZ within the following 90  days, compared with 78 in the 
control period 31–120  days before exposure, yielding an 
incidence ratio of 0.76 (95% CI, .54–1.06). Furthermore, 
the proportion of outpatient healthcare contacts attributed 
to HZ was not higher than in the control period (relative 
risk 0.99; 95% CI, .70–1.39). In contrast, in 3 case-control 
studies, which included 101–389 HZ case patients and 101–
511 controls, ORs ranged between 2.64 and 3.40 for self-re-
ported negative life events in the previous 3–6 months [4, 5, 
7]. Similarly, in a cohort study of 4162 elderly volunteers, an 
increased hazard ratio of HZ (1.38; 95% CI, .96–1.97) was 
observed among persons who reported negative life events in 
the prior 1–4 years [6]. The discrepancy between the results 
from these interview-based studies and our study, as well as 
the previous self-controlled case series, may be explained 
by important methodological differences, including use of 
aggregate measures for negative life events [4–7], potential 
self-selection bias [4–7], lack of interviewer blinding [4, 5, 
7], potential recall bias [4, 5, 7], and limited sample sizes 
[4–7].
Immunological studies show that bereavement is asso-
ciated with functional cellular immune deficiency [3]. Our 
study suggests that this effect may not be clinically significant 
for triggering HZ, because the overall upper confidence limit 
was only 7% in Denmark and the early fluctuations in ORs are 
compatible with delayed healthcare seeking among bereaved 
persons. Nevertheless, it is possible that other types of psycho-
logical stress, such as that associated with psychiatric illness, 
elicit different immune responses than those observed after 
the, predominantly acute, stress of partner bereavement [3]. 
For example, it has been demonstrated that persons with major 
depression have reduced cell-mediated immunity against the 
varicella zoster virus [35–37].
Major strengths of our study include the large study size, use 
of prospectively collected data from 2 separate tax-supported 
healthcare systems, and availability of detailed data on tempo-
rality of exposure and outcome. However, several limitations 
need to be considered. We believe that delayed healthcare 
contact immediately after loss explains the potential transient 
decrease in the ORs within 14 days after bereavement. We 
anticipated that such delay could introduce bias in the Danish 
study, because patients who present late with HZ may not be 
prescribed antivirals [22], thus omitting them from study inclu-
sion. Another concern for the prescription-based algorithm is 
misclassification of herpes simplex, which might be provoked 
Table 2. Odds Ratio for Association Between Partner Bereavement and Herpes Zoster
Bereavement Status
Denmark United Kingdom
Case Patients, 
No. (%)
Controls,  
No. (%)
Unadjusted  
OR (99% CI)
Adjusted  
OR (99% CI)a
Case Patients, 
No. (%)
Controls,  
No. (%)
Unadjusted  
OR (99% CI)
Adjusted  
OR (99% CI)a
Never bereaved 157 076 (82.4) 633 082 (83.0) Reference Reference 141 774 (94.4) 544 495 (94.4) Reference Reference
Bereaved, by duration of bereavement
 Total 33 595 (17.6) 129 602 (17.0) 1.06 (1.04–1.08) 1.05 (1.03–1.07) 8433 (5.6) 32 383 (5.6) 1.01 (.98–1.05) 1.01 (.98–1.05)
 0–7 d 26 (0.01) 159 (0.02) 0.66 (.38–1.15) 0.67 (.38–1.15) 16 (0.01) 77 (0.01) 0.81 (.40–1.64) 0.82 (.40–1.67)
 8–14 d 31 (0.02) 126 (0.02) 1.00 (.60–1.68) 1.03 (.61–1.73) 13 (0.01) 74 (0.01) 0.69 (.32–1.50) 0.69 (.32–1.50)
 15–30 d 90 (0.05) 367 (0.05) 1.00 (.73–1.35) 1.01 (.74–1.37) 52 (0.03) 165 (0.03) 1.24 (.82–1.87) 1.26 (.84–1.91)
 31–90 d 343 (0.2) 1273 (0.2) 1.09 (.94–1.28) 1.10 (.94–1.29) 171 (0.1) 629 (0.1) 1.06 (.85–1.32) 1.05 (.84–1.32)
 91–365 d 1572 (0.8) 5977 (0.8) 1.07 (.99–1.15) 1.07 (.99–1.15) 746 (0.5) 2956 (0.5) 0.98 (.88–1.09) 0.98 (.88–1.09)
 366–1095 d 3989 (2.1) 15 322 (2.0) 1.06 (1.01–1.11) 1.06 (1.01–1.11) 1755 (1.2) 6712 (1.2) 1.02 (.95–1.09) 1.02 (.95–1.09)
 >1095 d 27 544 (14.4) 106 378 (13.9) 1.06 (1.03–1.08) 1.05 (1.03–1.07) 5680 (3.8) 21 770 (3.8) 1.02 (.97–1.06) 1.01 (.97–1.05)
Abbreviations: CI, confidence interval; OR, odds ratio. 
aAdjusted for rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, diabetes, chronic kidney disease, human immu-
nodeficiency virus infection, hematopoietic stem cell/bone marrow transplantation, solid organ transplantation, other cellular immune deficiency, leukemia, lymphoma, myeloma, oral 
glucocorticoids, other immunosuppressant drugs, and inhaled glucocorticoids.
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by acute stress [1]. Nevertheless, the similarity between results 
observed in Denmark and the United Kingdom, including the 
initial decrease in the OR, suggests that such these biases are 
negligible.
Misclassification of partner bereavement is possible, in par-
ticular in the United Kingdom where data used for identifying 
partners were less detailed than in Denmark. Use of the gen-
eral practice family number to identify cohabitating persons 
may have affected the completeness of our algorithm, as some 
partners may not be registered with the same general prac-
tice. Nevertheless, our results remained robust after exclud-
ing single persons from the reference group. Furthermore, the 
prevalence of previous bereavement was remarkably similar 
in the Danish and UK data. The only difference was a lower 
prevalence in the United Kingdom >1 year before the index 
date, which is consistent with the shorter observation period 
in the CPRD.
A previous study reported that, according to contemporary 
national representative household surveys in England, 99% of 
cohabitating persons aged ≥60 years who are of the opposite sex 
and have an age difference of <10 years identify themselves as 
partners [28]. Although these data support a high accuracy of 
our algorithm, some couples may have represented cohabitating 
friends or siblings. Still, such misclassification would capture 
bereavement of a significant person in someone’s life, which is 
also likely to be stressful.
Finally, imprecise estimates limited identification of effect 
measure modification by the partner’s risk of death. Expectation 
of death is also difficult to categorize and associated psycholog-
ical distress could depend on the type of chronic disease [10]. 
Any previous partner bereavement
Denmark
UK
Pooled odds ratio (I2 = 85%)
0–7 d
Denmark
UK
Pooled odds ratio (I2 = 0%)
8–14 d
Denmark
UK
Pooled odds ratio (I 2 = 19%)
15–30 d
Denmark
UK
Pooled odds ratio (I2 = 19%)
31–90 d
Denmark
UK
Pooled odds ratio (I2 = 0%)
91–365 d
Denmark
UK
Pooled odds ratio (I2 = 84%)
366–1095 d
Denmark
UK
Pooled odds ratio (I2 = 29%)
>1095 d
Denmark
UK
Pooled odds ratio (I2 = 81%)
1.05 (1.03 – 1.07)
1.01 (.98 – 1.05)
1.03 (.98 – 1.08)
0.67 (.38 – 1.15)
0.82 (.40 – 1.67)
0.72 (.47 – 1.12)
1.03 (.61 – 1.73)
0.69 (.32 – 1.50)
0.90 (.55 – 1.46)
1.01 (.74 – 1.37)
1.26 (.84 – 1.91)
1.10 (.83 – 1.45)
1.10 (.94 – 1.29)
1.05 (.84 – 1.32)
1.08 (.95 – 1.23)
1.07 (.99 – 1.15)
0.98 (.98 – 1.09)
1.02 (.91 – 1.14)
1.06 (1.01 – 1.11)
1.02 (.95 – 1.09)
1.04 (1.00 – 1.10)
1.05 (1.03 – 1.07)
1.01 (.97 – 1.05)
1.03 (.98 – 1.08)
  
10.2 0.5 2 4
Figure 2. Pooled adjusted odds ratios (99% confidence intervals) from meta-analysis of the association between partner bereavement and herpes zoster in the Danish and 
UK studies. Odds ratios were adjusted for rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, diabetes, 
chronic kidney disease, human immunodeficiency virus infection, hematopoietic stem cell/bone marrow transplantation, solid organ transplantation, other cellular immune 
deficiency, leukemia, lymphoma, myeloma, oral glucocorticoids, other immunosuppressant drugs, and inhaled glucocorticoids.
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Furthermore, because the majority of partners were considered 
at intermediate or high risk of death, the time of bereavement 
may not mark the beginning of the stressful period.
In conclusion, we found no evidence of a substantial increase 
in the risk of HZ after partner bereavement. The observed 
decrease in the relative risk of HZ within 14 days after bereave-
ment followed by corresponding increased risks within subse-
quent months is compatible with delayed healthcare contact 
due to the loss.
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Figure 3. Adjusted odds ratios (99% confidence intervals) for herpes zoster among persons experiencing partner bereavement within the previous 30 days compared with 
those who had never been bereaved, according to subgroups based on partner’s risk of death, sex, age at index date, and recent diagnosis of depression or anxiety. Odds ratios 
were adjusted for rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, diabetes, chronic kidney disease, 
human immunodeficiency virus infection, hematopoietic stem cell/bone marrow transplantation, solid organ transplantation, other cellular immune deficiency, leukaemia, 
lymphoma, myeloma, oral glucocorticoids, other immunosuppressant drugs, and inhaled glucocorticoids. The partner’s risk of death was computed using the age-adjusted 
Charlson Comorbidity Index score and categorized as low (0–3 points), intermediate (4–6 points), or high (≥7 points).
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